Since April 1, 2017, Ms. Curran has served as President, Global Inflammation and Immunology Franchise of Celgene Corporation, an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. Previously, she was Head of Worldwide Markets for the I&I Franchise. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful U.S. launch of OTEZLA®. Before Celgene, she served as Senior Vice President and General Manager — Global Women’s Health business at Merck and Co., Inc. At Merck, she was responsible for all commercial activities within the global business and led a number of successful global product launches. Prior to Merck, Ms. Curran was a General Manager at Schering-Plough where she successfully launched Remicade in Switzerland and Australia. From March 2014 to March 2017, Ms. Curran served as a director of H. Lundbeck A/S, a global pharmaceutical company specialized in psychiatric and neurological disorders. Ms. Curran received her BS and Graduate Diploma of Marketing degrees from the University of Technology in Sydney, Australia.

Mr. Guinan has served as a member of our board since September 2018. Since July 2013, Mr. Guinan has served as the Executive Vice President and Chief Financial Officer at Quest Diagnostics Incorporated, a provider of diagnostic information services. From 2010 to 2013, he served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the health care industry. Previously, he served in a number of finance and operations roles in a long career at Johnson & Johnson including as Vice President, Chief Procurement Officer, and as the CFO of the pharmaceutical business. Before joining Johnson & Johnson in 1997, Mr. Guinan held a number of financial roles at Procter & Gamble. He received his BA in economics from the University of Notre Dame and his MBA from Olin Business School at the Washington University in St. Louis.

Ms. Potter has served as a member of our board since September 2018. Since July 2018, Ms. Potter has served as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences consulting firm in 2005 and served as the Chief Executive Officer until she joined Roivant. She previously served as President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech. Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol-Myers Squibb. She is a graduate of the University of Chicago. In addition to serving on our Board, Ms. Potter also serves on the boards of Arbutus Biopharma Corp., Urovant Sciences Ltd., Axovant Sciences Ltd., Liberty Mutual Holdings Company, Inc., Axsome Therapeutics, Inc., and a number of privately held companies. Ms. Potter also previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc.

Mr. Ramaswamy is Founder and Chief Executive Officer of Roivant Sciences. Roivant is focused on rapidly developing innovative medicines through a novel form of industrial organization in R&D. Roivant’s mission is to systemically reduce the time and cost of drug development and to advance important medicines for patients in disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal needs. With its affiliates, Roivant has raised over $3 billion in capital to date to fund clinical programs and pursue adjacent business opportunities in healthcare. Prior to founding Roivant in 2014, Mr. Ramaswamy was an investor in the biotechnology sector and an entrepreneur. He received his AB summa cum laude in biology from Harvard College and his JD from Yale Law School, where he was a Paul & Daisy Soros Fellow.

Ms. Sebelius has served as a member of our board since October 2016. From April 2009 to June 2014, Ms. Sebelius served as U.S. Secretary of Health and Human Services (HHS). As Secretary of HHS, she presided over 11 operating divisions, including the CDC, FDA, and NIH and oversaw the passage and implementation of the Affordable Care Act. Before joining President Obama’s cabinet, Ms. Sebelius served as Governor of Kansas, elected in 2002 and re-elected in 2006. She had previously been elected twice as the Kansas Insurance Commissioner and from 1987 to 1995 served in the Kansas House of Representatives. Ms. Sebelius also currently serves as a director of Dermira Inc., a medical dermatology company, and Exact Sciences Inc., a cancer diagnostics company. She is a trustee of the Kaiser Family Foundation and co-chairs the Health Strategy Group for the Aspen Institute. Ms. Sebelius received a BA in political science from Trinity Washington University and a Master of Public Administration from the University of Kansas.

Dr. Seely is the Principal Executive Officer of Myovant Sciences Ltd. and the President and Chief Executive Officer of Myovant Sciences, Inc. From March 2005 to October 2015, Dr. Seely served as Chief Medical Officer of Medivation, Inc., a biopharmaceutical company, where she served on the Executive Committee and led the development of XTANDI® for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely was responsible for building the clinical organization at Medivation, Inc., as well as the regulatory, quality, project management, medical affairs and biologics manufacturing functions. Dr. Seely previously served as Vice President of Clinical Development at Anesiva, Inc. (formerly Corgentech), a biopharmaceutical company, and at Cytyc Health Corporation, a medical device company. In addition, she currently serves as a director of Blueprint Medicines Corporation, a biotechnology company. Dr. Seely received her BA in Journalism from the University of Oklahoma and her MD from the University of Oklahoma College of Medicine and completed her residency in internal medicine at Yale-New Haven Hospital. After serving as Chief Resident in Internal Medicine at Yale University School of Medicine, she completed her basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.

Dr. Torti has served as a member of our board since November 2018. Since August 2018, Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a division of Roivant Sciences. Prior to Roivant, Dr. Torti was a partner at New Enterprise Associates (NEA), a leading venture capital firm. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices. Prior to joining NEA, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trials research and economic evaluations of multinational clinical trials. In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences. Dr. Torti received his MD from the University of North Carolina School of Medicine and his MBA with distinction from Harvard Business School.